Eucreas

Eucreas (vildagliptin + metformin) is a new fixed-dose combination treatment for patients inadequately controlled on metformin alone or in patients who are already treated with the components as separate tablets.

Eucreas is available as film-coated tablets containing vildagliptin 50mg plus metformin hydrochloride 850mg or 1000mg.

Eucreas should be given twice daily. Patients receiving vildagliptin and metformin as separate tablets may switch to the equivalent Eucreas tablet; those on metformin alone should be initiated on the strength of Eucreas tablet that matches their current metformin dose.

View Eucreas drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Last chance to register for the next Respiratory and Allergy Learning Series event

Last chance to register for the next Respiratory and Allergy Learning Series event

Join Dr Steve Holmes, who will be chairing the MIMS...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Accrete D3.
Use our constantly updated...

Don't prescribe antibiotics for non-bullous impetigo, draft NICE guidance advises

Don't prescribe antibiotics for non-bullous impetigo, draft NICE guidance advises

Topical antiseptics are preferable to antibiotics for...

Contraceptives

Contraceptives

Hormone doses and costs of hormonal contraceptives.